Business ❯Corporate Transactions
Technology Companies Divestitures Private Equity International Business Steel Industry Stake Sales Technology Acquisitions Asset Sales ByteDance Food Industry
Adaptimmune retains its two preclinical T cell therapies after selling Tecelra plus two clinical-stage programs in a $55 million deal that shifts commercialization staff to U.S. WorldMeds.